Table 2.
Distribution of antimicrobial susceptibility of the E. coli and K. pneumoniae isolates to and non β-lactam antibiotics
| Antimicrobial agents | E.coli | K. pneumoniae | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| n (%) | ||||||
| β-lactams | S | I | R | S | I | R |
| Ampicillin | 44 (29.5) | 1 (0.7) | 104 (69.8) | 3 (2.7) | 2 (1.8) | 105 (95.5) |
| Amoxicillin/Clavulanic Acid | 104 (69.8) | 21 (14.1) | 24 (16.1) | 67 (60.9) | 9 (8.2) | 34 (30.9) |
| Piperacillin | 86 (57.7) | 2 (1.3) | 61 (41.0) | 50 (45.5) | 12 (10.9) | 48 (43.6) |
| Piperacillin/Tazobactam | 134 (90.0) | 2 (1.3) | 13 (8.7) | 76 (69.1) | 5 (4.5) | 29 (26.4) |
| Sulbactam/Ampicillin | 106 (71.1) | 8 (5.4) | 35 (23.5) | 72 (65.5) | 2 (1.8) | 36 (32.7) |
| Cefotaxime | 116 (77.9) | 0 (0.0) | 33 (22.1) | 70 (63.6) | 1 (0.9) | 39 (35.5) |
| Ceftazidime | 126 (84.6) | 0 (0.0) | 23 (15.4) | 71 (64.5) | 1 (1.0) | 38 (34.5) |
| Cefepime | 128 (85.9) | 5 (3.4) | 16 (10.7) | 77 (70.0) | 2 (1.8) | 31(28.2) |
| Cefuroxime | 114 (76.5) | 1 (0.7) | 34 (22.8) | 67 (60.9) | 4 (3.6) | 39 (35.5) |
| Meropenem | 149 (100) | 0 (0.0) | 0 (0.0) | 106 (96.4) | 0 (0.0) | 4 (3.6) |
| Imipenem | 149 (100) | 0 (0.0) | 0 (0.0) | 106 (96.4) | 0 (0.0) | 4 (3.6) |
| Ertapenem | 148 (99.3) | 0 (0.0) | 1 (0.7) | 105 (95.5) | 0 (0.0) | 5 (4.5) |
|
| ||||||
| Non β-lactams | S | I | R | S | I | R |
|
| ||||||
| Amikacin | 149 (100) | 0 (0.0) | 0 (0.0) | 106 (96.4) | 0 (0.0) | 4 (3.6) |
| Ciprofloxacin | 123 (82.5) | 4 (2.7) | 22 (14.8) | 78 (70.9) | 10 (9.1) | 22 (20.0) |
| Gentamicin | 131 (87.9) | 0 (0.0) | 18 (12.1) | 81 (73.6) | 1 (0.9) | 28 (25.5) |
| Chloramphenicol | 122 (81.9) | 1 (0.7) | 26 (17.4) | 86 (78.2) | 0 (0.0) | 24 (21.8) |
| polymyxin B | 144 (96.6) | 0 (0.0) | 5 (3.4) | 95 (86.4) | 0 (0.0) | 15 (13.6) |
| Trimethoprim-Sulfamethoxazole | 79 (53.0) | 1(0.7) | 69 (46.3) | 66 (60.0) | 2 (1.8) | 42 (38.2) |